来源:发现报告(www.fxbaogao.com/view?id=5788630)| 引用请注明出处White PaperTargeting Residual Risk: The Next Wave of Cardiovascular, Renal and Metabolic Innovation Beyond obesity, a strategic outlook on the CVRM pipeline, market and routes to commercial successMARKUS GORES, Vice President, Thought Leadership, IQVIASTEFAN LUTZMAYER, Senior Consultant, Thought Leadership, IQVIASOPHIE MARLOW, Summer Intern, Thought Leadership, IQVIA来源:发现报告(www.fxbaogao.com/view?id=5788630)| 引用请注明出处Table of contentsIntroduction 1The CVRM opportunity: Unmet need, and complexity, continue to rise 2The unique complexity of the CVRM opportunity 3The CVRM pipeline and innovation highlights 5The competitive landscape in CVRM 7Deep dive: CVRM innovation highlights 9I. Dyslipidaemias 9II. Hypertension 13Outlook for the CVRM market 16How to succeed as CVRM innovator 18About the authors 20References 21来源:发现报告(www.fxbaogao.com/view?id=5788630)| 引用请注明出处 iqvia.com | 1IntroductionSince the publication of our white paper ‘A renaissance for cardiometabolic innovation’ in 2023, the biopharmaceutical industry’s renewed interest in an area it had largely neglected for much of the previous two decades has yielded some remarkable breakthroughs.1Incretin-based pharmacotherapies have truly transformed weight management, unleashed extraordinary consumer demand and propelled obesity up the ranks to become the fourth largest therapy area by value, generating $66Bn in global sales in 2025, at ex-manufacturer prices.Meanwhile, Madrigal made history in March 2024 when the FDA approved its oral, thyroid hormone receptor beta agonist Rezdiffra as the first therapy for metabolic dysfunction-associated steatohepatitis (MASH), which had become a notorious graveyard for drug development.In May 2026, AstraZeneca’s Baxfendy was approved for the treatment of hypertension, introducing the first aldosterone synthase inhibitor to this market and bringing hope to the many patients inadequately served by existing therapy options.These examples clearly illustrate that innovation focused on cardiovascular-renal-metabolic (CVRM) diseases is alive and well and delivers transformational benefits for patients.But there is more to do. CVRM risk factors continue to be among the leading drivers of both global mortality and the burden of disease and thus represent key targets for effectively managing population health.In this white paper, we will explore the latest trends in CVRM innovation, including a deep dive into selected therapeutic breakthroughs, and provide an outlook on the competitive landscape and the CVRM market opportunity.Since obesity, understandably, is often the centre of attention and extensively covered in many reviews, we will focus in this white paper on ex-obesity CVRM innovation, while acknowledging the interdependencies with obesity therapies as they impact a range of CVRM risk factors beyond BMI.来源:发现报告...